52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FDA Says Abbott Vascular Recalls NC Trek RX And NC Traveler RX Coronary Dilatation Catheters Due To Failure Of Balloon To Deflate
Abbott & Insulet Partner to Integrate Next-Generation Glucose Sensing & Automated Insulin Delivery Technologies
Abbott Laboratories Says It Expects Mid- To High Single-Digit Growth In Established Pharmaceuticals In Both Q1 And Full Year 2020- Conf. Call
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
100 Abbott Park Rd
Miles D. White
Chairman of the Board, Chief Executive Officer
Robert B. Ford
President, Chief Operating Officer
Brian B. Yoor
Chief Financial Officer, Executive Vice President - Finance
Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* ABBOTT AND INSULET PARTNER TO INTEGRATE NEXT-GENERATION GLUCOSE SENSING AND AUTOMATED INSULIN DELIVERY TECHNOLOGIES FOR DIABETES CARE
* ABBOTT LABORATORIES - RECEIVED CE MARK FOR NEW GALLANT IMPLANTABLE CARDIOVERTER DEFIBRILLATOR AND CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR DEVICES Source text for Eikon: Further company coverage:
Abbott Laboratories Inc's <ABT.N> shares rose to an all-time high on Wednesday after the device maker beat Wall Street estimates for quarterly sales on higher demand for its nutrition products and generic drugs.
Abbott Laboratories' <ABT.N> incoming Chief Executive Officer Robert Ford said on Wednesday that deal-making was not on the company's agenda.
Abbott Laboratories' incoming Chief Executive Officer Robert Ford said on Wednesday that deal-making was not on the company's agenda. "On the M&A side, we're not looking to do any deals right now," Ford, who currently serves as chief operating officer, said on a conference...
Abbott Laboratories <ABT.N> longtime Chief Executive Officer Miles White will step down in favour of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.
Abbott Laboratories said on Wednesday Chief Executive Officer Miles White would step down next year and be replaced by Chief Operating Officer Robert Ford.
The U.S. Food and Drug Administration on Monday classified the recall of Abbott Laboratories' CentriMag blood pumping system following the death of a patient, as Class 1 or the most serious type of recall.
Abbott Laboratories <ABT.N> fell just short of Wall Street estimates for quarterly revenue on Wednesday, as weakness in the medical device maker's cardiovascular business overshadowed strong performance in its fast-growing diabetes care unit.
Abbott Laboratories <ABT.N> beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.
Abbott Laboratories <ABT.N> plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.
Abbott Laboratories <ABT.N> missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
Healthcare company Abbott Laboratories <ABT.N> will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.
Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.